---
document_datetime: 2025-12-02 05:09:03
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/amlodipine-valsartan-mylan.html
document_name: amlodipine-valsartan-mylan.html
version: success
processing_time: 0.1615372
conversion_datetime: 2025-12-24 05:49:35.231844
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Amlodipine  / Valsartan Mylan

[RSS](/en/individual-human-medicine.xml/65957)

##### Authorised

This medicine is authorised for use in the European Union

amlodipine / valsartan Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Amlodipine / Valsartan Mylan](#news-on)
- [More information on Amlodipine / Valsartan Mylan](#more-information-on-amlodipine-valsartan-mylan-1157)
- [Related information](#related-information-572)
- [Product information - with tracked changes](#product-information-with-tracked-changes-77468)
- [More information on Amlodipine / Valsartan Mylan](#related-medicines)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

This is a summary of the European public assessment report (EPAR) for Amlodipine/Valsartan Mylan. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Amlodipine/Valsartan Mylan.

For practical information about using Amlodipine/Valsartan Mylan, patients should read the package leaflet or contact their doctor or pharmacist.

Expand section

Collapse section

## What is Amlodipine/Valsartan Mylan and what is it used for?

Amlodipine/Valsartan Mylan is a medicine used in patients who have essential hypertension (high blood pressure) that is not adequately controlled on either amlodipine or valsartan taken alone. 'Essential' means that the hypertension has no obvious cause.

Amlodipine/Valsartan Mylan contains two active substances, amlodipine and valsartan. It is a 'generic medicine'. This means that Amlodipine/Valsartan Mylan is similar to a 'reference medicine' already authorised in the European Union (EU) called Exforge.

## How is Amlodipine/Valsartan Mylan used?

Amlodipine/Valsartan Mylan is available as tablets (5 mg amlodipine and 80 mg valsartan; 5 mg amlodipine and 160 mg valsartan; 10 mg amlodipine and 160 mg valsartan). One tablet is taken daily by mouth with water. It is recommended that the patient takes amlodipine and valsartan as separate tablets or capsules before switching to the combination tablet. The strength of the tablet to be used depends on the doses of amlodipine or valsartan that the patient was taking before.

The medicine can only be obtained with a prescription.

## How does Amlodipine/Valsartan Mylan work?

Amlodipine/Valsartan Mylan contains two active substances, amlodipine and valsartan. Both are anti-hypertensive medicines that have been available separately in the European Union (EU) since the mid-1990s. They work in similar ways to reduce blood pressure by allowing the blood vessels to relax. By lowering the blood pressure, the risks associated with high blood pressure, such as having a stroke, are reduced.

Amlodipine is a calcium channel blocker. It blocks special channels on the surface of cells through which calcium normally enters the cells. When calcium enters the cells in the muscles of blood vessel walls, this causes contraction. By reducing the flow of calcium into the cells, amlodipine prevents the cells from contracting and this helps the blood vessels to relax.

Valsartan is an 'angiotensin II receptor antagonist', which means that it blocks the action of a hormone in the body called angiotensin II. Angiotensin II is a powerful vasoconstrictor (a substance that narrows blood vessels). By blocking the receptors to which angiotensin II normally attaches, valsartan stops the hormone having an effect, allowing the blood vessels to widen.

## How has Amlodipine/Valsartan Mylan been studied?

Because Amlodipine/Valsartan Mylan is a generic medicine, studies in people have been limited to tests to determine that it is bioequivalent to the reference medicine, Exforge. Two medicines are bioequivalent when they produce the same levels of the active substance in the body.

## What are the benefits and risks of Amlodipine/Valsartan Mylan?

Because Amlodipine/Valsartan Mylan is a generic medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine's.

## Why is Amlodipine/Valsartan Mylan approved?

The Agency's Committee for Medicinal Products for Human Use (CHMP) concluded that, in accordance with EU requirements, Amlodipine/Valsartan Mylan has been shown to have comparable quality and to be bioequivalent/be comparable to Exforge. Therefore, the CHMP's view was that, as for Exforge, the benefit outweighs the identified risk. The Committee recommended that Amlodipine/Valsartan Mylan be approved for use in the EU.

## What measures are being taken to ensure the safe and effective use of Amlodipine/Valsartan Mylan?

A risk management plan has been developed to ensure that Amlodipine/Valsartan Mylan is used as safely as possible. Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Amlodipine/Valsartan Mylan, including the appropriate precautions to be followed by healthcare professionals and patients.

## Other information about Amlodipine/Valsartan Mylan

The European Commission granted a marketing authorisation valid throughout the European Union for Amlodipine/Valsartan Mylan on 22 March 2016.

For more information about treatment with Amlodipine/Valsartan Mylan, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.

Amlodipine  / Valsartan Mylan  : EPAR - Summary for the public

English (EN) (92.77 KB - PDF)

**First published:** 06/04/2016

**Last updated:** 06/04/2016

[View](/en/documents/overview/amlodipine-valsartan-mylan-epar-summary-public_en.pdf)

[Other languages (22)](#file-language-dropdown-549)

български (BG) (121.4 KB - PDF)

**First published:**

06/04/2016

**Last updated:**

06/04/2016

[View](/bg/documents/overview/amlodipine-valsartan-mylan-epar-summary-public_bg.pdf)

español (ES) (92.3 KB - PDF)

**First published:**

06/04/2016

**Last updated:**

06/04/2016

[View](/es/documents/overview/amlodipine-valsartan-mylan-epar-summary-public_es.pdf)

čeština (CS) (117.07 KB - PDF)

**First published:**

06/04/2016

**Last updated:**

06/04/2016

[View](/cs/documents/overview/amlodipine-valsartan-mylan-epar-summary-public_cs.pdf)

dansk (DA) (90.95 KB - PDF)

**First published:**

06/04/2016

**Last updated:**

06/04/2016

[View](/da/documents/overview/amlodipine-valsartan-mylan-epar-summary-public_da.pdf)

Deutsch (DE) (93.2 KB - PDF)

**First published:**

06/04/2016

**Last updated:**

06/04/2016

[View](/de/documents/overview/amlodipine-valsartan-mylan-epar-summary-public_de.pdf)

eesti keel (ET) (90.03 KB - PDF)

**First published:**

06/04/2016

**Last updated:**

06/04/2016

[View](/et/documents/overview/amlodipine-valsartan-mylan-epar-summary-public_et.pdf)

ελληνικά (EL) (123.84 KB - PDF)

**First published:**

06/04/2016

**Last updated:**

06/04/2016

[View](/el/documents/overview/amlodipine-valsartan-mylan-epar-summary-public_el.pdf)

français (FR) (92.88 KB - PDF)

**First published:**

06/04/2016

**Last updated:**

06/04/2016

[View](/fr/documents/overview/amlodipine-valsartan-mylan-epar-summary-public_fr.pdf)

hrvatski (HR) (109.98 KB - PDF)

**First published:**

06/04/2016

**Last updated:**

06/04/2016

[View](/hr/documents/overview/amlodipine-valsartan-mylan-epar-summary-public_hr.pdf)

italiano (IT) (91.65 KB - PDF)

**First published:**

06/04/2016

**Last updated:**

06/04/2016

[View](/it/documents/overview/amlodipine-valsartan-mylan-epar-summary-public_it.pdf)

latviešu valoda (LV) (113 KB - PDF)

**First published:**

06/04/2016

**Last updated:**

06/04/2016

[View](/lv/documents/overview/amlodipine-valsartan-mylan-epar-summary-public_lv.pdf)

lietuvių kalba (LT) (113.38 KB - PDF)

**First published:**

06/04/2016

**Last updated:**

06/04/2016

[View](/lt/documents/overview/amlodipine-valsartan-mylan-epar-summary-public_lt.pdf)

magyar (HU) (111.4 KB - PDF)

**First published:**

06/04/2016

**Last updated:**

06/04/2016

[View](/hu/documents/overview/amlodipine-valsartan-mylan-epar-summary-public_hu.pdf)

Malti (MT) (116.64 KB - PDF)

**First published:**

06/04/2016

**Last updated:**

06/04/2016

[View](/mt/documents/overview/amlodipine-valsartan-mylan-epar-summary-public_mt.pdf)

Nederlands (NL) (92.47 KB - PDF)

**First published:**

06/04/2016

**Last updated:**

06/04/2016

[View](/nl/documents/overview/amlodipine-valsartan-mylan-epar-summary-public_nl.pdf)

polski (PL) (118.8 KB - PDF)

**First published:**

06/04/2016

**Last updated:**

06/04/2016

[View](/pl/documents/overview/amlodipine-valsartan-mylan-epar-summary-public_pl.pdf)

português (PT) (92.43 KB - PDF)

**First published:**

06/04/2016

**Last updated:**

06/04/2016

[View](/pt/documents/overview/amlodipine-valsartan-mylan-epar-summary-public_pt.pdf)

română (RO) (114.09 KB - PDF)

**First published:**

06/04/2016

**Last updated:**

06/04/2016

[View](/ro/documents/overview/amlodipine-valsartan-mylan-epar-summary-public_ro.pdf)

slovenčina (SK) (116.21 KB - PDF)

**First published:**

06/04/2016

**Last updated:**

06/04/2016

[View](/sk/documents/overview/amlodipine-valsartan-mylan-epar-summary-public_sk.pdf)

slovenščina (SL) (109.99 KB - PDF)

**First published:**

06/04/2016

**Last updated:**

06/04/2016

[View](/sl/documents/overview/amlodipine-valsartan-mylan-epar-summary-public_sl.pdf)

Suomi (FI) (90.46 KB - PDF)

**First published:**

06/04/2016

**Last updated:**

06/04/2016

[View](/fi/documents/overview/amlodipine-valsartan-mylan-epar-summary-public_fi.pdf)

svenska (SV) (90.73 KB - PDF)

**First published:**

06/04/2016

**Last updated:**

06/04/2016

[View](/sv/documents/overview/amlodipine-valsartan-mylan-epar-summary-public_sv.pdf)

Amlodipine / Valsartan Mylan : EPAR - Risk management plan

English (EN) (244.94 KB - PDF)

**First published:** 24/09/2024

[View](/en/documents/rmp/amlodipine-valsartan-mylan-epar-risk-management-plan_en.pdf)

## Product information

Amlodipine / Valsartan Mylan : EPAR - Product Information

English (EN) (404.7 KB - PDF)

**First published:** 06/04/2016

**Last updated:** 24/07/2025

[View](/en/documents/product-information/amlodipine-valsartan-mylan-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-737)

български (BG) (517.18 KB - PDF)

**First published:**

06/04/2016

**Last updated:**

24/07/2025

[View](/bg/documents/product-information/amlodipine-valsartan-mylan-epar-product-information_bg.pdf)

español (ES) (504.63 KB - PDF)

**First published:**

06/04/2016

**Last updated:**

24/07/2025

[View](/es/documents/product-information/amlodipine-valsartan-mylan-epar-product-information_es.pdf)

čeština (CS) (668.87 KB - PDF)

**First published:**

06/04/2016

**Last updated:**

24/07/2025

[View](/cs/documents/product-information/amlodipine-valsartan-mylan-epar-product-information_cs.pdf)

dansk (DA) (517.41 KB - PDF)

**First published:**

06/04/2016

**Last updated:**

24/07/2025

[View](/da/documents/product-information/amlodipine-valsartan-mylan-epar-product-information_da.pdf)

Deutsch (DE) (303.05 KB - PDF)

**First published:**

06/04/2016

**Last updated:**

24/07/2025

[View](/de/documents/product-information/amlodipine-valsartan-mylan-epar-product-information_de.pdf)

eesti keel (ET) (364.68 KB - PDF)

**First published:**

06/04/2016

**Last updated:**

24/07/2025

[View](/et/documents/product-information/amlodipine-valsartan-mylan-epar-product-information_et.pdf)

ελληνικά (EL) (438.98 KB - PDF)

**First published:**

06/04/2016

**Last updated:**

24/07/2025

[View](/el/documents/product-information/amlodipine-valsartan-mylan-epar-product-information_el.pdf)

français (FR) (494.87 KB - PDF)

**First published:**

06/04/2016

**Last updated:**

24/07/2025

[View](/fr/documents/product-information/amlodipine-valsartan-mylan-epar-product-information_fr.pdf)

hrvatski (HR) (648.93 KB - PDF)

**First published:**

06/04/2016

**Last updated:**

24/07/2025

[View](/hr/documents/product-information/amlodipine-valsartan-mylan-epar-product-information_hr.pdf)

íslenska (IS) (528.07 KB - PDF)

**First published:**

06/04/2016

**Last updated:**

24/07/2025

[View](/is/documents/product-information/amlodipine-valsartan-mylan-epar-product-information_is.pdf)

italiano (IT) (371.29 KB - PDF)

**First published:**

06/04/2016

**Last updated:**

24/07/2025

[View](/it/documents/product-information/amlodipine-valsartan-mylan-epar-product-information_it.pdf)

latviešu valoda (LV) (462.57 KB - PDF)

**First published:**

06/04/2016

**Last updated:**

24/07/2025

[View](/lv/documents/product-information/amlodipine-valsartan-mylan-epar-product-information_lv.pdf)

lietuvių kalba (LT) (444.2 KB - PDF)

**First published:**

06/04/2016

**Last updated:**

24/07/2025

[View](/lt/documents/product-information/amlodipine-valsartan-mylan-epar-product-information_lt.pdf)

magyar (HU) (622.52 KB - PDF)

**First published:**

06/04/2016

**Last updated:**

24/07/2025

[View](/hu/documents/product-information/amlodipine-valsartan-mylan-epar-product-information_hu.pdf)

Malti (MT) (672.03 KB - PDF)

**First published:**

06/04/2016

**Last updated:**

24/07/2025

[View](/mt/documents/product-information/amlodipine-valsartan-mylan-epar-product-information_mt.pdf)

Nederlands (NL) (648.93 KB - PDF)

**First published:**

06/04/2016

**Last updated:**

24/07/2025

[View](/nl/documents/product-information/amlodipine-valsartan-mylan-epar-product-information_nl.pdf)

norsk (NO) (535.42 KB - PDF)

**First published:**

06/04/2016

**Last updated:**

24/07/2025

[View](/no/documents/product-information/amlodipine-valsartan-mylan-epar-product-information_no.pdf)

polski (PL) (508.72 KB - PDF)

**First published:**

06/04/2016

**Last updated:**

24/07/2025

[View](/pl/documents/product-information/amlodipine-valsartan-mylan-epar-product-information_pl.pdf)

português (PT) (347.71 KB - PDF)

**First published:**

06/04/2016

**Last updated:**

24/07/2025

[View](/pt/documents/product-information/amlodipine-valsartan-mylan-epar-product-information_pt.pdf)

română (RO) (650.97 KB - PDF)

**First published:**

06/04/2016

**Last updated:**

24/07/2025

[View](/ro/documents/product-information/amlodipine-valsartan-mylan-epar-product-information_ro.pdf)

slovenčina (SK) (625.17 KB - PDF)

**First published:**

06/04/2016

**Last updated:**

24/07/2025

[View](/sk/documents/product-information/amlodipine-valsartan-mylan-epar-product-information_sk.pdf)

slovenščina (SL) (382.71 KB - PDF)

**First published:**

06/04/2016

**Last updated:**

24/07/2025

[View](/sl/documents/product-information/amlodipine-valsartan-mylan-epar-product-information_sl.pdf)

Suomi (FI) (545.55 KB - PDF)

**First published:**

06/04/2016

**Last updated:**

24/07/2025

[View](/fi/documents/product-information/amlodipine-valsartan-mylan-epar-product-information_fi.pdf)

svenska (SV) (382.71 KB - PDF)

**First published:**

06/04/2016

**Last updated:**

24/07/2025

[View](/sv/documents/product-information/amlodipine-valsartan-mylan-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** VR/0000287321 23/07/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Amlodipine  / Valsartan Mylan  : EPAR - All Authorised presentations

English (EN) (92.25 KB - PDF)

**First published:** 06/04/2016

**Last updated:** 06/04/2016

[View](/en/documents/all-authorised-presentations/amlodipine-valsartan-mylan-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-494)

български (BG) (82.54 KB - PDF)

**First published:**

06/04/2016

**Last updated:**

06/04/2016

[View](/bg/documents/all-authorised-presentations/amlodipine-valsartan-mylan-epar-all-authorised-presentations_bg.pdf)

español (ES) (79.93 KB - PDF)

**First published:**

06/04/2016

**Last updated:**

06/04/2016

[View](/es/documents/all-authorised-presentations/amlodipine-valsartan-mylan-epar-all-authorised-presentations_es.pdf)

čeština (CS) (79.14 KB - PDF)

**First published:**

06/04/2016

**Last updated:**

06/04/2016

[View](/cs/documents/all-authorised-presentations/amlodipine-valsartan-mylan-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (75.41 KB - PDF)

**First published:**

06/04/2016

**Last updated:**

06/04/2016

[View](/da/documents/all-authorised-presentations/amlodipine-valsartan-mylan-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (75.98 KB - PDF)

**First published:**

06/04/2016

**Last updated:**

06/04/2016

[View](/de/documents/all-authorised-presentations/amlodipine-valsartan-mylan-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (80.02 KB - PDF)

**First published:**

06/04/2016

**Last updated:**

06/04/2016

[View](/et/documents/all-authorised-presentations/amlodipine-valsartan-mylan-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (88.85 KB - PDF)

**First published:**

06/04/2016

**Last updated:**

06/04/2016

[View](/el/documents/all-authorised-presentations/amlodipine-valsartan-mylan-epar-all-authorised-presentations_el.pdf)

français (FR) (75.47 KB - PDF)

**First published:**

06/04/2016

**Last updated:**

06/04/2016

[View](/fr/documents/all-authorised-presentations/amlodipine-valsartan-mylan-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (78.43 KB - PDF)

**First published:**

06/04/2016

**Last updated:**

06/04/2016

[View](/hr/documents/all-authorised-presentations/amlodipine-valsartan-mylan-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (75.04 KB - PDF)

**First published:**

06/04/2016

**Last updated:**

06/04/2016

[View](/is/documents/all-authorised-presentations/amlodipine-valsartan-mylan-epar-all-authorised-presentations_is.pdf)

italiano (IT) (73.25 KB - PDF)

**First published:**

06/04/2016

**Last updated:**

06/04/2016

[View](/it/documents/all-authorised-presentations/amlodipine-valsartan-mylan-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (80.59 KB - PDF)

**First published:**

06/04/2016

**Last updated:**

06/04/2016

[View](/lv/documents/all-authorised-presentations/amlodipine-valsartan-mylan-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (82.85 KB - PDF)

**First published:**

06/04/2016

**Last updated:**

06/04/2016

[View](/lt/documents/all-authorised-presentations/amlodipine-valsartan-mylan-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (84.64 KB - PDF)

**First published:**

06/04/2016

**Last updated:**

06/04/2016

[View](/hu/documents/all-authorised-presentations/amlodipine-valsartan-mylan-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (80.42 KB - PDF)

**First published:**

06/04/2016

**Last updated:**

06/04/2016

[View](/mt/documents/all-authorised-presentations/amlodipine-valsartan-mylan-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (73.44 KB - PDF)

**First published:**

06/04/2016

**Last updated:**

06/04/2016

[View](/nl/documents/all-authorised-presentations/amlodipine-valsartan-mylan-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (74.28 KB - PDF)

**First published:**

06/04/2016

**Last updated:**

06/04/2016

[View](/no/documents/all-authorised-presentations/amlodipine-valsartan-mylan-epar-all-authorised-presentations_no.pdf)

polski (PL) (76.44 KB - PDF)

**First published:**

06/04/2016

**Last updated:**

06/04/2016

[View](/pl/documents/all-authorised-presentations/amlodipine-valsartan-mylan-epar-all-authorised-presentations_pl.pdf)

português (PT) (76.54 KB - PDF)

**First published:**

06/04/2016

**Last updated:**

06/04/2016

[View](/pt/documents/all-authorised-presentations/amlodipine-valsartan-mylan-epar-all-authorised-presentations_pt.pdf)

română (RO) (77.86 KB - PDF)

**First published:**

06/04/2016

**Last updated:**

06/04/2016

[View](/ro/documents/all-authorised-presentations/amlodipine-valsartan-mylan-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (82.22 KB - PDF)

**First published:**

06/04/2016

**Last updated:**

06/04/2016

[View](/sk/documents/all-authorised-presentations/amlodipine-valsartan-mylan-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (88.26 KB - PDF)

**First published:**

06/04/2016

**Last updated:**

06/04/2016

[View](/sl/documents/all-authorised-presentations/amlodipine-valsartan-mylan-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (74.37 KB - PDF)

**First published:**

06/04/2016

**Last updated:**

06/04/2016

[View](/fi/documents/all-authorised-presentations/amlodipine-valsartan-mylan-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (73.62 KB - PDF)

**First published:**

06/04/2016

**Last updated:**

06/04/2016

[View](/sv/documents/all-authorised-presentations/amlodipine-valsartan-mylan-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Amlodipine  / Valsartan Mylan Active substance

- amlodipine besilate
- valsartan

International non-proprietary name (INN) or common name

- amlodipine
- valsartan

Therapeutic area (MeSH) Hypertension Anatomical therapeutic chemical (ATC) code C09DB01

### Pharmacotherapeutic group

Agents acting on the renin-angiotensin system

### Therapeutic indication

Treatment of essential hypertension.

Amlodipine/Valsartan Mylan is indicated in adults whose blood pressure is not adequately controlled on amlodipine or valsartan monotherapy.

## Authorisation details

EMA product number EMEA/H/C/004037

Generic

This is a generic medicine, which is developed to be the same as a medicine that has already been authorised, called the reference medicine. A generic medicine contains the same active substance(s) as the reference medicine, and is used at the same dose(s) to treat the same disease(s). For more information, see [Generic and hybrid medicines](/node/69107) .

Marketing authorisation holder

Mylan Pharmaceuticals Limited

Damastown Industrial Park,

Opinion adopted 28/01/2016 Marketing authorisation issued 22/03/2016 Revision 17

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Amlodipine / Valsartan Mylan : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (528.93 KB - PDF)

**First published:** 12/05/2025

**Last updated:** 24/07/2025

[View](/en/documents/procedural-steps-after/amlodipine-valsartan-mylan-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf-0)

Amlodipine  / Valsartan Mylan  : EPAR - Procedural steps taken and scientific information after authorisation (archive)

English (EN) (131.9 KB - PDF)

**First published:** 06/02/2017

**Last updated:** 24/07/2025

[View](/en/documents/procedural-steps-after/amlodipine-valsartan-mylan-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

Angiotensin-II-receptor antagonists (sartans) : Scientific conclusions - Impact of the Article 5(3) scientific opinion on nitrosamines

Adopted

English (EN) (119.28 KB - PDF)

**First published:** 05/07/2021

[View](/en/documents/scientific-conclusion/angiotensin-ii-receptor-antagonists-sartans-scientific-conclusions-impact-article-53-scientific-opinion-nitrosamines_en.pdf)

[Other languages (22)](#file-language-dropdown-984)

български (BG) (145.18 KB - PDF)

**First published:**

05/07/2021

[View](/bg/documents/scientific-conclusion/angiotensin-ii-receptor-antagonists-sartans-scientific-conclusions-impact-article-53-scientific-opinion-nitrosamines_bg.pdf)

español (ES) (125.85 KB - PDF)

**First published:**

05/07/2021

[View](/es/documents/scientific-conclusion/angiotensin-ii-receptor-antagonists-sartans-scientific-conclusions-impact-article-53-scientific-opinion-nitrosamines_es.pdf)

čeština (CS) (139.02 KB - PDF)

**First published:**

05/07/2021

[View](/cs/documents/scientific-conclusion/angiotensin-ii-receptor-antagonists-sartans-scientific-conclusions-impact-article-53-scientific-opinion-nitrosamines_cs.pdf)

dansk (DA) (126.81 KB - PDF)

**First published:**

05/07/2021

[View](/da/documents/scientific-conclusion/angiotensin-ii-receptor-antagonists-sartans-scientific-conclusions-impact-article-53-scientific-opinion-nitrosamines_da.pdf)

Deutsch (DE) (131.05 KB - PDF)

**First published:**

05/07/2021

[View](/de/documents/scientific-conclusion/angiotensin-ii-receptor-antagonists-sartans-scientific-conclusions-impact-article-53-scientific-opinion-nitrosamines_de.pdf)

eesti keel (ET) (123.85 KB - PDF)

**First published:**

05/07/2021

[View](/et/documents/scientific-conclusion/angiotensin-ii-receptor-antagonists-sartans-scientific-conclusions-impact-article-53-scientific-opinion-nitrosamines_et.pdf)

ελληνικά (EL) (139.5 KB - PDF)

**First published:**

05/07/2021

[View](/el/documents/scientific-conclusion/angiotensin-ii-receptor-antagonists-sartans-scientific-conclusions-impact-article-53-scientific-opinion-nitrosamines_el.pdf)

français (FR) (127.12 KB - PDF)

**First published:**

05/07/2021

[View](/fr/documents/scientific-conclusion/angiotensin-ii-receptor-antagonists-sartans-scientific-conclusions-impact-article-53-scientific-opinion-nitrosamines_fr.pdf)

hrvatski (HR) (142.87 KB - PDF)

**First published:**

05/07/2021

[View](/hr/documents/scientific-conclusion/angiotensin-ii-receptor-antagonists-sartans-scientific-conclusions-impact-article-53-scientific-opinion-nitrosamines_hr.pdf)

italiano (IT) (126.56 KB - PDF)

**First published:**

05/07/2021

[View](/it/documents/scientific-conclusion/angiotensin-ii-receptor-antagonists-sartans-scientific-conclusions-impact-article-53-scientific-opinion-nitrosamines_it.pdf)

latviešu valoda (LV) (147.7 KB - PDF)

**First published:**

05/07/2021

[View](/lv/documents/scientific-conclusion/angiotensin-ii-receptor-antagonists-sartans-scientific-conclusions-impact-article-53-scientific-opinion-nitrosamines_lv.pdf)

lietuvių kalba (LT) (148.34 KB - PDF)

**First published:**

05/07/2021

[View](/lt/documents/scientific-conclusion/angiotensin-ii-receptor-antagonists-sartans-scientific-conclusions-impact-article-53-scientific-opinion-nitrosamines_lt.pdf)

magyar (HU) (137.17 KB - PDF)

**First published:**

05/07/2021

[View](/hu/documents/scientific-conclusion/angiotensin-ii-receptor-antagonists-sartans-scientific-conclusions-impact-article-53-scientific-opinion-nitrosamines_hu.pdf)

Malti (MT) (151.21 KB - PDF)

**First published:**

05/07/2021

[View](/mt/documents/scientific-conclusion/angiotensin-ii-receptor-antagonists-sartans-scientific-conclusions-impact-article-53-scientific-opinion-nitrosamines_mt.pdf)

Nederlands (NL) (127.53 KB - PDF)

**First published:**

05/07/2021

[View](/nl/documents/scientific-conclusion/angiotensin-ii-receptor-antagonists-sartans-scientific-conclusions-impact-article-53-scientific-opinion-nitrosamines_nl.pdf)

polski (PL) (137.7 KB - PDF)

**First published:**

05/07/2021

[View](/pl/documents/scientific-conclusion/angiotensin-ii-receptor-antagonists-sartans-scientific-conclusions-impact-article-53-scientific-opinion-nitrosamines_pl.pdf)

português (PT) (128.87 KB - PDF)

**First published:**

05/07/2021

[View](/pt/documents/scientific-conclusion/angiotensin-ii-receptor-antagonists-sartans-scientific-conclusions-impact-article-53-scientific-opinion-nitrosamines_pt.pdf)

română (RO) (143.59 KB - PDF)

**First published:**

05/07/2021

[View](/ro/documents/scientific-conclusion/angiotensin-ii-receptor-antagonists-sartans-scientific-conclusions-impact-article-53-scientific-opinion-nitrosamines_ro.pdf)

slovenčina (SK) (135.07 KB - PDF)

**First published:**

05/07/2021

[View](/sk/documents/scientific-conclusion/angiotensin-ii-receptor-antagonists-sartans-scientific-conclusions-impact-article-53-scientific-opinion-nitrosamines_sk.pdf)

slovenščina (SL) (149.74 KB - PDF)

**First published:**

05/07/2021

[View](/sl/documents/scientific-conclusion/angiotensin-ii-receptor-antagonists-sartans-scientific-conclusions-impact-article-53-scientific-opinion-nitrosamines_sl.pdf)

Suomi (FI) (125.84 KB - PDF)

**First published:**

05/07/2021

[View](/fi/documents/scientific-conclusion/angiotensin-ii-receptor-antagonists-sartans-scientific-conclusions-impact-article-53-scientific-opinion-nitrosamines_fi.pdf)

svenska (SV) (126.99 KB - PDF)

**First published:**

05/07/2021

[View](/sv/documents/scientific-conclusion/angiotensin-ii-receptor-antagonists-sartans-scientific-conclusions-impact-article-53-scientific-opinion-nitrosamines_sv.pdf)

Angiotensin-II-receptor antagonists (sartans) Article 31 referral - CHMP assessment report - Impact of the Article 5(3) scientific opinion on nitrosamines

Adopted

Reference Number: EMA/47245/2021

English (EN) (362.31 KB - PDF)

**First published:** 02/03/2021

[View](/en/documents/variation-report/angiotensin-ii-receptor-antagonists-sartans-article-31-referral-chmp-assessment-report-impact-article-53-scientific-opinion-nitrosamines_en.pdf)

Amlodipine / Valsartan Mylan : EPAR - Scientific conclusions

English (EN) (99.42 KB - PDF)

**First published:** 21/05/2019

[View](/en/documents/scientific-conclusion/amlodipine-valsartan-mylan-epar-scientific-conclusions_en.pdf)

[Other languages (22)](#file-language-dropdown-279)

български (BG) (136.15 KB - PDF)

**First published:**

21/05/2019

[View](/bg/documents/scientific-conclusion/amlodipine-valsartan-mylan-epar-scientific-conclusions_bg.pdf)

español (ES) (98.31 KB - PDF)

**First published:**

21/05/2019

[View](/es/documents/scientific-conclusion/amlodipine-valsartan-mylan-epar-scientific-conclusions_es.pdf)

čeština (CS) (131.08 KB - PDF)

**First published:**

21/05/2019

[View](/cs/documents/scientific-conclusion/amlodipine-valsartan-mylan-epar-scientific-conclusions_cs.pdf)

dansk (DA) (96.12 KB - PDF)

**First published:**

21/05/2019

[View](/da/documents/scientific-conclusion/amlodipine-valsartan-mylan-epar-scientific-conclusions_da.pdf)

Deutsch (DE) (100.2 KB - PDF)

**First published:**

21/05/2019

[View](/de/documents/scientific-conclusion/amlodipine-valsartan-mylan-epar-scientific-conclusions_de.pdf)

eesti keel (ET) (94.4 KB - PDF)

**First published:**

21/05/2019

[View](/et/documents/scientific-conclusion/amlodipine-valsartan-mylan-epar-scientific-conclusions_et.pdf)

ελληνικά (EL) (142.79 KB - PDF)

**First published:**

21/05/2019

[View](/el/documents/scientific-conclusion/amlodipine-valsartan-mylan-epar-scientific-conclusions_el.pdf)

français (FR) (97.56 KB - PDF)

**First published:**

21/05/2019

[View](/fr/documents/scientific-conclusion/amlodipine-valsartan-mylan-epar-scientific-conclusions_fr.pdf)

hrvatski (HR) (125.02 KB - PDF)

**First published:**

21/05/2019

[View](/hr/documents/scientific-conclusion/amlodipine-valsartan-mylan-epar-scientific-conclusions_hr.pdf)

italiano (IT) (95.54 KB - PDF)

**First published:**

21/05/2019

[View](/it/documents/scientific-conclusion/amlodipine-valsartan-mylan-epar-scientific-conclusions_it.pdf)

latviešu valoda (LV) (130.68 KB - PDF)

**First published:**

21/05/2019

[View](/lv/documents/scientific-conclusion/amlodipine-valsartan-mylan-epar-scientific-conclusions_lv.pdf)

lietuvių kalba (LT) (130.84 KB - PDF)

**First published:**

21/05/2019

[View](/lt/documents/scientific-conclusion/amlodipine-valsartan-mylan-epar-scientific-conclusions_lt.pdf)

magyar (HU) (119.82 KB - PDF)

**First published:**

21/05/2019

[View](/hu/documents/scientific-conclusion/amlodipine-valsartan-mylan-epar-scientific-conclusions_hu.pdf)

Malti (MT) (133.78 KB - PDF)

**First published:**

21/05/2019

[View](/mt/documents/scientific-conclusion/amlodipine-valsartan-mylan-epar-scientific-conclusions_mt.pdf)

Nederlands (NL) (99.3 KB - PDF)

**First published:**

21/05/2019

[View](/nl/documents/scientific-conclusion/amlodipine-valsartan-mylan-epar-scientific-conclusions_nl.pdf)

polski (PL) (130.65 KB - PDF)

**First published:**

21/05/2019

[View](/pl/documents/scientific-conclusion/amlodipine-valsartan-mylan-epar-scientific-conclusions_pl.pdf)

português (PT) (96.47 KB - PDF)

**First published:**

21/05/2019

[View](/pt/documents/scientific-conclusion/amlodipine-valsartan-mylan-epar-scientific-conclusions_pt.pdf)

română (RO) (128.25 KB - PDF)

**First published:**

21/05/2019

[View](/ro/documents/scientific-conclusion/amlodipine-valsartan-mylan-epar-scientific-conclusions_ro.pdf)

slovenčina (SK) (119.14 KB - PDF)

**First published:**

21/05/2019

[View](/sk/documents/scientific-conclusion/amlodipine-valsartan-mylan-epar-scientific-conclusions_sk.pdf)

slovenščina (SL) (124.14 KB - PDF)

**First published:**

21/05/2019

[View](/sl/documents/scientific-conclusion/amlodipine-valsartan-mylan-epar-scientific-conclusions_sl.pdf)

Suomi (FI) (97.12 KB - PDF)

**First published:**

21/05/2019

[View](/fi/documents/scientific-conclusion/amlodipine-valsartan-mylan-epar-scientific-conclusions_fi.pdf)

svenska (SV) (96.85 KB - PDF)

**First published:**

21/05/2019

[View](/sv/documents/scientific-conclusion/amlodipine-valsartan-mylan-epar-scientific-conclusions_sv.pdf)

Angiotensin-II-receptor antagonists (sartans) Article 31 referral - CHMP assessment report

Adopted

Reference Number: EMA/217823/2019

English (EN) (531.32 KB - PDF)

**First published:** 02/05/2019

[View](/en/documents/variation-report/angiotensin-ii-receptor-antagonists-sartans-article-31-referral-chmp-assessment-report_en.pdf)

## Initial marketing authorisation documents

Amlodipine  / Valsartan Mylan  : EPAR - Public assessment report

Adopted

Reference Number: EMA/CHMP/182030/2016

English (EN) (801.78 KB - PDF)

**First published:** 06/04/2016

**Last updated:** 06/04/2016

[View](/en/documents/assessment-report/amlodipine-valsartan-mylan-epar-public-assessment-report_en.pdf)

CHMP summary of opinion for Amlodipine-Valsartan Mylan

Adopted

Reference Number: EMA/CHMP/18049/2016

English (EN) (68.07 KB - PDF)

**First published:** 29/01/2016

**Last updated:** 29/01/2016

[View](/en/documents/smop-initial/chmp-summary-opinion-amlodipine-valsartan-mylan_en.pdf)

#### News on Amlodipine  / Valsartan Mylan

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 25-28 January 2016](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-25-28-january-2016) 29/01/2016

#### More information on Amlodipine / Valsartan Mylan

Questions and answers on generic medicines

Reference Number: EMA/393905/2006 Rev. 2

English (EN) (66.45 KB - PDF)

**First published:** 09/07/2007

**Last updated:** 07/12/2012

[View](/en/documents/other/questions-and-answers-generic-medicines_en.pdf)

[Other languages (22)](#file-language-dropdown-211)

български (BG) (93.16 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/bg/documents/other/questions-and-answers-generic-medicines_bg.pdf)

español (ES) (68.3 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/es/documents/other/questions-and-answers-generic-medicines_es.pdf)

čeština (CS) (87.71 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/cs/documents/other/questions-and-answers-generic-medicines_cs.pdf)

dansk (DA) (66.79 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/da/documents/other/questions-and-answers-generic-medicines_da.pdf)

Deutsch (DE) (67.55 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/de/documents/other/questions-and-answers-generic-medicines_de.pdf)

eesti keel (ET) (65.21 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/et/documents/other/questions-and-answers-generic-medicines_et.pdf)

ελληνικά (EL) (91.29 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/el/documents/other/questions-and-answers-generic-medicines_el.pdf)

français (FR) (68.35 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/fr/documents/other/questions-and-answers-generic-medicines_fr.pdf)

hrvatski (HR) (87.8 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/hr/documents/other/questions-and-answers-generic-medicines_hr.pdf)

italiano (IT) (67.62 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/it/documents/other/questions-and-answers-generic-medicines_it.pdf)

latviešu valoda (LV) (111.81 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/lv/documents/other/questions-and-answers-generic-medicines_lv.pdf)

lietuvių kalba (LT) (86.76 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/lt/documents/other/questions-and-answers-generic-medicines_lt.pdf)

magyar (HU) (85.76 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/hu/documents/other/questions-and-answers-generic-medicines_hu.pdf)

Malti (MT) (89.35 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/mt/documents/other/questions-and-answers-generic-medicines_mt.pdf)

Nederlands (NL) (66.81 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/nl/documents/other/questions-and-answers-generic-medicines_nl.pdf)

polski (PL) (88.51 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/pl/documents/other/questions-and-answers-generic-medicines_pl.pdf)

português (PT) (68.32 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/pt/documents/other/questions-and-answers-generic-medicines_pt.pdf)

română (RO) (86.9 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/ro/documents/other/questions-and-answers-generic-medicines_ro.pdf)

slovenčina (SK) (87.73 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sk/documents/other/questions-and-answers-generic-medicines_sk.pdf)

slovenščina (SL) (84.8 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sl/documents/other/questions-and-answers-generic-medicines_sl.pdf)

Suomi (FI) (66.21 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/fi/documents/other/questions-and-answers-generic-medicines_fi.pdf)

svenska (SV) (67.11 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sv/documents/other/questions-and-answers-generic-medicines_sv.pdf)

#### Related information

- [Clinical data](https://clinicaldata.ema.europa.eu/web/cdp/search?p_p_id=cdpdossierviewportlet_WAR_cdpdossierviewportlet=0=maximized=view=column-1=1=EMEAHC0040370000) (initial marketing authorisation)

#### Product information - with tracked changes

The approved product information for this medicine is available below showing the changes since the previous procedure affecting the product information. The same document without tracked changes is above under 'Product information'.

Amlodipine / Valsartan Mylan : EPAR - Product information - tracked changes

English (EN) (149.52 KB - DOCX)

**First published:** 20/06/2025

**Last updated:** 24/07/2025

[View](/en/documents/product-information-tracked-changes/amlodipine-valsartan-mylan-epar-product-information-tracked-changes_en.docx)

[Other languages (24)](#file-language-dropdown-208)

български (BG) (172.63 KB - DOCX)

**First published:**

20/06/2025

**Last updated:**

24/07/2025

[View](/bg/documents/product-information-tracked-changes/amlodipine-valsartan-mylan-epar-product-information-tracked-changes_bg.docx)

español (ES) (143.5 KB - DOCX)

**First published:**

20/06/2025

**Last updated:**

24/07/2025

[View](/es/documents/product-information-tracked-changes/amlodipine-valsartan-mylan-epar-product-information-tracked-changes_es.docx)

čeština (CS) (155.17 KB - DOCX)

**First published:**

20/06/2025

**Last updated:**

24/07/2025

[View](/cs/documents/product-information-tracked-changes/amlodipine-valsartan-mylan-epar-product-information-tracked-changes_cs.docx)

dansk (DA) (154.88 KB - DOCX)

**First published:**

20/06/2025

**Last updated:**

24/07/2025

[View](/da/documents/product-information-tracked-changes/amlodipine-valsartan-mylan-epar-product-information-tracked-changes_da.docx)

Deutsch (DE) (142.26 KB - DOCX)

**First published:**

20/06/2025

**Last updated:**

24/07/2025

[View](/de/documents/product-information-tracked-changes/amlodipine-valsartan-mylan-epar-product-information-tracked-changes_de.docx)

eesti keel (ET) (126.56 KB - DOCX)

**First published:**

20/06/2025

**Last updated:**

24/07/2025

[View](/et/documents/product-information-tracked-changes/amlodipine-valsartan-mylan-epar-product-information-tracked-changes_et.docx)

ελληνικά (EL) (158.5 KB - DOCX)

**First published:**

20/06/2025

**Last updated:**

24/07/2025

[View](/el/documents/product-information-tracked-changes/amlodipine-valsartan-mylan-epar-product-information-tracked-changes_el.docx)

français (FR) (142.38 KB - DOCX)

**First published:**

20/06/2025

**Last updated:**

24/07/2025

[View](/fr/documents/product-information-tracked-changes/amlodipine-valsartan-mylan-epar-product-information-tracked-changes_fr.docx)

hrvatski (HR) (143.82 KB - DOCX)

**First published:**

20/06/2025

**Last updated:**

24/07/2025

[View](/hr/documents/product-information-tracked-changes/amlodipine-valsartan-mylan-epar-product-information-tracked-changes_hr.docx)

íslenska (IS) (156.66 KB - DOCX)

**First published:**

20/06/2025

**Last updated:**

24/07/2025

[View](/is/documents/product-information-tracked-changes/amlodipine-valsartan-mylan-epar-product-information-tracked-changes_is.docx)

italiano (IT) (142.19 KB - DOCX)

**First published:**

20/06/2025

**Last updated:**

24/07/2025

[View](/it/documents/product-information-tracked-changes/amlodipine-valsartan-mylan-epar-product-information-tracked-changes_it.docx)

latviešu valoda (LV) (137.78 KB - DOCX)

**First published:**

20/06/2025

**Last updated:**

24/07/2025

[View](/lv/documents/product-information-tracked-changes/amlodipine-valsartan-mylan-epar-product-information-tracked-changes_lv.docx)

lietuvių kalba (LT) (157.03 KB - DOCX)

**First published:**

20/06/2025

**Last updated:**

24/07/2025

[View](/lt/documents/product-information-tracked-changes/amlodipine-valsartan-mylan-epar-product-information-tracked-changes_lt.docx)

magyar (HU) (131.53 KB - DOCX)

**First published:**

20/06/2025

**Last updated:**

24/07/2025

[View](/hu/documents/product-information-tracked-changes/amlodipine-valsartan-mylan-epar-product-information-tracked-changes_hu.docx)

Malti (MT) (161.78 KB - DOCX)

**First published:**

20/06/2025

**Last updated:**

24/07/2025

[View](/mt/documents/product-information-tracked-changes/amlodipine-valsartan-mylan-epar-product-information-tracked-changes_mt.docx)

Nederlands (NL) (156.74 KB - DOCX)

**First published:**

20/06/2025

**Last updated:**

24/07/2025

[View](/nl/documents/product-information-tracked-changes/amlodipine-valsartan-mylan-epar-product-information-tracked-changes_nl.docx)

norsk (NO) (149.18 KB - DOCX)

**First published:**

20/06/2025

**Last updated:**

24/07/2025

[View](/no/documents/product-information-tracked-changes/amlodipine-valsartan-mylan-epar-product-information-tracked-changes_no.docx)

polski (PL) (144.94 KB - DOCX)

**First published:**

20/06/2025

**Last updated:**

24/07/2025

[View](/pl/documents/product-information-tracked-changes/amlodipine-valsartan-mylan-epar-product-information-tracked-changes_pl.docx)

português (PT) (133.94 KB - DOCX)

**First published:**

20/06/2025

**Last updated:**

24/07/2025

[View](/pt/documents/product-information-tracked-changes/amlodipine-valsartan-mylan-epar-product-information-tracked-changes_pt.docx)

română (RO) (164.43 KB - DOCX)

**First published:**

20/06/2025

**Last updated:**

24/07/2025

[View](/ro/documents/product-information-tracked-changes/amlodipine-valsartan-mylan-epar-product-information-tracked-changes_ro.docx)

slovenčina (SK) (153.23 KB - DOCX)

**First published:**

20/06/2025

**Last updated:**

24/07/2025

[View](/sk/documents/product-information-tracked-changes/amlodipine-valsartan-mylan-epar-product-information-tracked-changes_sk.docx)

slovenščina (SL) (144.8 KB - DOCX)

**First published:**

20/06/2025

**Last updated:**

24/07/2025

[View](/sl/documents/product-information-tracked-changes/amlodipine-valsartan-mylan-epar-product-information-tracked-changes_sl.docx)

Suomi (FI) (158.03 KB - DOCX)

**First published:**

20/06/2025

**Last updated:**

24/07/2025

[View](/fi/documents/product-information-tracked-changes/amlodipine-valsartan-mylan-epar-product-information-tracked-changes_fi.docx)

svenska (SV) (153.39 KB - DOCX)

**First published:**

20/06/2025

**Last updated:**

24/07/2025

[View](/sv/documents/product-information-tracked-changes/amlodipine-valsartan-mylan-epar-product-information-tracked-changes_sv.docx)

#### More information on Amlodipine  / Valsartan Mylan

- [Angiotensin-II-receptor antagonists (sartans) containing a tetrazole group - referral](/en/medicines/human/referrals/angiotensin-ii-receptor-antagonists-sartans-containing-tetrazole-group)

#### Topics

- [Generic and hybrid medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A54)
- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 24/07/2025

## Share this page

[Back to top](#main-content)